US · Healthcare · Biotechnology
EPS came in at 4.73 against a street estimate of -0.56 — a beat of 944.6%.
Analysts rate Nurix Therapeutics Inc a strong buy (13 buy, 1 hold, 0 sell out of 14) with an average price target of $34.36.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.45% |
| Vestal Point Capital LP | 7.76% |
| Deep Track Capital, LP | 7.45% |
| Rubric Capital Management LP | 6.96% |
| FMR Inc | 5.29% |
| T. Rowe Price Associates, Inc. | 5.24% |
| Morgan Stanley - Brokerage Accounts | 4.59% |
| State Street Corp | 4.51% |
| Document | Date |
|---|---|
| Quarterly report · Q3 FY2026 HEADLINE NUMBERS • For the nine months ended August 31, 2026, total revenue was $688,359 thousand, compared with $70,403 thousand in the prior-year p | 2026-10-13 |
| Results announced · Q4 FY2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $673.1 million, versus $7.9 million in the third quarter of 2025, primarily reflecting $653.2 milli | 2026-10-13 |
| Quarterly report · Q2 FY2026 NURIX THERAPEUTICS, INC. – FORM 10-Q SUMMARY For Quarter Ended May 31, 2026 --- HEADLINE NUMBERS • Cash and marketable securities combined: $443.5 | 2026-07-09 |
| Results announced · Q3 FY2026 NURIX THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $443.5 million in cash, cash equivalents and marketable secur | 2026-07-09 |
| Reg FD disclosure · Q3 FY2026 NURIX THERAPEUTICS, INC. - FORM 8-K SUMMARY Date of Report: June 11, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • Drug Program: Bexobrutideg (NX-5948), | 2026-06-11 |
| Material agreement · Q3 FY2026 NURIX THERAPEUTICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Upfront payment from Roche: $700.0 million cash to Nurix • Total potential payments: | 2026-06-08 |
| Shareholder vote results · Q2 FY2026 NURIX THERAPEUTICS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 15, 2026 with 83,747,013 shares present or by proxy • Quorum | 2026-05-15 |
| Quarterly report · Q1 FY2026 NURIX THERAPEUTICS, INC. - Q1 2026 (ENDED FEBRUARY 28, 2026) SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Cash & Marketable Securities: $71. | 2026-04-08 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Nurix Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.